“we're expecting to get a full German population access in Q1 2025.”

In context

“the eligible pregnant women in just one quarter in Q4. In France, in competitive setting, Abrysvo was administered to over 40% of the eligible pregnant women in the Q4 alone. So clearly, we see a potential as we move into 2025 in the MI, great opportunity to expand usage and to expand the vaccination. And of course, that is not just in the developed market, but also in emerging markets. And for instance, as you know, Abrysvo was listed at the Pan-America Health Organization. And so starting this year, we can have Latin American country to start contracting Abrysvo. Now in the OA, we start also to see some traction and the vaccination campaign in the U.K. already reached 44% of the eligible population and regional vaccination was granted late 2024 in about half of the German population and we're expecting to get a full German population access in Q1 2025. So again, on both maternal immunization and order adults, plenty of opportunity to grow. Albert Bourla: Thank you. Next question, please. Operator: We'll go next to Vamil Divan with Guggenheim Securities. Please go ahead. Vamil Divan: Yes, great. Thanks for taking my questions. So maybe a couple if I could on the pipeline. So Prevnar 25-valent you mentioned starting Phase 3 in adults this year. Just curious if you can comment on what you've seen so far gives you comfort in moving up for when we might see the data publicly. And also any updates on the pediatric population and when you -- where things stand there. And then the second one is on Ponsegromab. And just you have the, obviously, cancer cachexia, which you're starting Phase 3, we also noticed in the Phase 2 heart failure program,”